Successful Treatment with Transdermal Buprenorphine Patch in Opioid-Dependent Cancer Patients: Case Series |
Go, Se-Il
(Division of Hematology-Oncology, Department of Internal Medicine, Gyeongsang National University Changwon Hospital, Gyeongsang National University School of Medicine)
Kim, Jung Hoon (Division of Hematology-Oncology, Department of Internal Medicine, Gyeongsang National University School of Medicine) Lee, Gyeong-Won (Division of Hematology-Oncology, Department of Internal Medicine, Gyeongsang National University School of Medicine) Kang, Jung Hun (Division of Hematology-Oncology, Department of Internal Medicine, Gyeongsang National University School of Medicine) |
1 | van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol 2007;18:1437-49. DOI |
2 | Te Boveldt N, Vernooij-Dassen M, Burger N, Ijsseldijk M, Vissers K, Engels Y. Pain and its interference with daily activities in medical oncology outpatients. Pain Physician 2013;16:379-89. |
3 | Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, et al. Early palliative care for patients with metastatic non-smallcell lung cancer. N Engl J Med 2010;363:733-42. DOI |
4 | Ripamonti CI, Santini D, Maranzano E, Berti M, Roila F; ESMO Guidelines Working Group. Management of cancer pain: ESMO Clinical Practice Guidelines. Ann Oncol 2012;23 Suppl 7:vii139-54. DOI |
5 | Hojsted J, Sjogren P. Addiction to opioids in chronic pain patients: a literature review. Eur J Pain 2007;11:490-518. DOI |
6 | Anghelescu DL, Ehrentraut JH, Faughnan LG. Opioid misuse and abuse: risk assessment and management in patients with cancer pain. J Natl Compr Canc Netw 2013;11:1023-31. DOI |
7 | Kampman K, Jarvis M. American Society of Addiction Medicine (ASAM) National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use. J Addict Med 2015;9:358-67. DOI |
8 | Allain F, Minogianis EA, Roberts DC, Samaha AN. How fast and how often: The pharmacokinetics of drug use are decisive in addiction. Neurosci Biobehav Rev 2015;56:166-79. DOI |
9 | Go S-I, Kang JH, editors. Safety issue in opioid use. 2018 KCSG Cancer Care Symposium; 2018 Feb 24; Seoul, Republic of Korea. Seooul: Korean Cancer Study Group; 2018. |
10 | Apelt SM, Scherbaum N, Golz J, Backmund M, Soyka M. Safety, effectiveness and tolerance of buprenorphine-naloxone in the treatment of opioid dependence: results from a nationwide non-interventional study in routine care. Pharmacopsychiatry 2013;46:94-107. DOI |
11 | Park EM, Suzuki J. Treatment of opioid dependence and cancer pain with sublingual buprenorphine: a case report. Am J Addict 2012;21:283-4. DOI |
12 | Kalivas PW, O'Brien C. Drug addiction as a pathology of staged neuroplasticity. Neuropsychopharmacology 2008;33:166-80. DOI |
13 | Veilleux JC, Colvin PJ, Anderson J, York C, Heinz AJ. A review of opioid dependence treatment: pharmacological and psychosocial interventions to treat opioid addiction. Clin Psychol Rev 2010;30:155-66. DOI |
14 | Go SI, Song HN, Lee SJ, Bruera E, Kang JH. Craving behavior from opioid addiction controlled with olanzapine in an advanced cancer patient: a case report. J Palliat Med 2018;21:1367-70. DOI |
15 | Rehni AK, Jaggi AS, Singh N. Opioid withdrawal syndrome: emerging concepts and novel therapeutic targets. CNS Neurol Disord Drug Targets 2013;12:112-25. DOI |
16 | Kim JH, Song H, Lee G-W, Kang JH. Opioid withdrawal symptoms after conversion to oral oxycodone/naloxone in advanced cancer patients receiving strong opioids. Korean J Hosp Palliat Care 2017;20:131-5. DOI |
17 | Kircher S, Zacny J, Apfelbaum SM, Passik S, Kirsch K, Burbage M, et al. Understanding and treating opioid addiction in a patient with cancer pain. J Pain 2011;12:1025-31. DOI |
18 | Gunderson EW, Levin FR, Rombone MM, Vosburg SK, Kleber HD. Improving temporal efficiency of outpatient buprenorphine induction. Am J Addict 2011;20:397-404. DOI |
19 | Bonhomme J, Shim RS, Gooden R, Tyus D, Rust G. Opioid addiction and abuse in primary care practice: a comparison of methadone and buprenorphine as treatment options. J Natl Med Assoc 2012;104:342-50. DOI |
20 | Soyka M. Treatment of opioid dependence with buprenorphine: current update. Dialogues Clin Neurosci 2017;19:299-308. |
21 | Saxon AJ, Ling W, Hillhouse M, Thomas C, Hasson A, Ang A, et al. Buprenorphine/Naloxone and methadone effects on laboratory indices of liver health: a randomized trial. Drug Alcohol Depend 2013;128:71-6. DOI |
22 | Liebschutz JM, Crooks D, Herman D, Anderson B, Tsui J, Meshesha LZ, et al. Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial. JAMA Intern Med 2014;174:1369-76. DOI |
23 | HIRA [Internet]. Wonju: Health Insurance Review & Assessment Service; c2000-2018 [cited 2018 May 18]. Available from: http://www.hira.or.kr. |
24 | Hser YI, Saxon AJ, Huang D, Hasson A, Thomas C, Hillhouse M, et al. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Addiction 2014;109:79-87. DOI |
25 | Symons J, Myles PS, Mehra R, Ball CM. Perioperative medicine for the junior clinician. 1st ed. Chichester:John Wiley & Sons, Ltd;2015. |